Global implementation of genomic medicine:We are not alone by Manolio, Teri A. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1126/scitranslmed.aab0194
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Manolio, T. A., Abramowicz, M., Al-Mulla, F., Anderson, W., Balling, R., Berger, A. C., ... Ginsburg, G. S. (2015).
Global implementation of genomic medicine: We are not alone. Science Translational Medicine, 7(290),
[290ps13]. 10.1126/scitranslmed.aab0194
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
Global	Implementation	of	Genomic	Medicine:	We	Are	Not	Alone	
	
Running	title:	Global	Implementation	of	Genomic	Medicine	
	
Teri	A.	Manolio,	M.D.,	Ph.D.1,	Marc	Abramowicz,	M.D.,	Ph.D.	2,	Fahd	Al-Mulla,	M.D.,	Ph.D.3,	
Warwick	Anderson,	Ph.D.4,	Rudi	Balling,	Ph.D.5,	Adam	C.	Berger,	Ph.D.6,	Aravinda	Chakravarti,	
Ph.D.7,	Wasun	Chantratita,	Ph.D.8,	Rex	L.	Chisholm,	Ph.D.9,	Vajira	H.	W.	Dissanayake,	M.B.B.S.,	
Ph.D.10,	Victor	J.	Dzau,	M.D.11,	Thierry	Frebourg,	M.D.,	Ph.D.12,	Bok-Ghee	Han,	Ph.D.13,	Tim	
Hubbard,	Ph.D.14, Anne	Kolbe,	MB.BS.	FRACS15,	Bruce	Korf,	M.D.,	Ph.D.16,	Michiaki	Kubo,	M.D.,	
Ph.D.17,		Paul	Lasko,	Ph.D.18,	Erkki	Leego,	M.S.19,	Surakameth	Mahasirimongkol,	M.D.,	M.Sc.,	
Ph.D.20,	Partha	P.	Majumdar,	Ph.D.21,	Gert	Matthijs,	Ph.D.22,	Howard	L.	McLeod,	Pharm.D.23,	
Andres	Metspalu,	M.D.,	Ph.D.19,	Pierre	Meulien,	Ph.D.24,	Satoru	Miyano,	Ph.D.25,	Kevin	Moses,	
Ph.D.26,	Yaakov	Naparstek,	M.D.27,	Irene	Norstedt28,	P.	Pearl	O’Rourke,	M.D.29,	George	P.	
Patrinos,	Ph.D.30,	Heidi	L.	Rehm,	Ph.D.31,	Mary	V.	Relling,	Pharm.	D.32,	Gad	Rennert,	M.D.,	
Ph.D.33,	Laura	Lyman	Rodriguez,	Ph.D.1,	Dan	M.	Roden,	M.D.	34,	Alan	R.	Shuldiner,	M.D.35,	
Sukdev	Sinha36,	Patrick	Tan,	M.D.,	Ph.D.37,		Mats	Ulfendahl,	Ph.D.38,	Robyn	Ward,	M.D.39,	Marc	
S.	Williams,	M.D.40,	John	E.L	Wong,	M.B.B.S.41,	Eric	D.	Green,	M.D.,	Ph.D.1,	Geoffrey	S.	Ginsburg,	
M.D.,	Ph.D.42	
	
1	National	Human	Genome	Research	Institute,	National	Institutes	of	Health,	Bethesda,	MD	
2	Université	Libre	de	Bruxelles,	Belgium	
3	Genatak-Global	Med	Clinic,	Kuwait	University,	Kuwait	
4	National	Health	and	Medical	Research	Council,	Australia	
5	Luxembourg	Centre	for	Systems	Biomedicine,	University	of	Luxembourg,	Luxembourg	
6	Board	on	Health	Sciences	Policy,	Institute	of	Medicine,	Washington	DC	
7	McKusick-Nathans	Institute	of	Genetic	Medicine,	John	Hopkins	University	School	of	Medicine,	
Baltimore,	MD	
8	Ramathibodi	Hospital,	Mahidol	University,	Thailand	
2 
 
9	Center	for	Genetic	Medicine,	Northwestern	University	Feinberg	School	of	Medicine,	Chicago,	
IL		
10	Human	Genetics	Unit,	Faculty	of	Medicine,	University	of	Colombo,	Sri	Lanka	
11	Duke	University	Health	System,	Duke	University,	Durham	NC	
12	Department	of	Genetics,	Rouen	University	Hospital,	Rouen,	France			
13	Center	for	Genome	Science,	Korea	National	Institute	of	Health,	Korea	
14	Department	of	Medical	and	Molecular	Genetics,	King's	College,	United	Kingdom	
15	National	Health	Committee,	New	Zealand	
16	Center	for	Genomic	Science,	University	of	Alabama	at	Birmingham,	Birmingham	AL	
17	Center	for	Integrative	Medical	Science	(IMS),	RIKEN,	Japan	
18	Institute	of	Genetics,	Canadian	Institutes	of	Health	Research	and	McGill	University,	Montreal,	
Canada	
19	Estonian	Genome	Center,	University	of	Tartu,	Estonia	
20	Department	of	Medical	Science,	Ministry	of	Public	Health,	Thailand	
21	National	Institute	of	Biomedical	Genomics	and	Indian	Statistical	Institute,	India	
22	Center	for	Human	Genetics,	University	of	Leuven	(KU	Leuven),	Belgium	
23	DeBartolo	Family	Personalized	Medicine	Institute,	Moffitt	Cancer	Center,	FL	
24	Genome	Canada,	Canada	
25	Institute	of	Medical	Science,	University	of	Tokyo,	Tokyo,	Japan	
26	Science	Funding,	The	Wellcome	Trust,	United	Kingdom	
27	Research	and		Academic	Affairs,	Hadassah	University	Hospital,	Israel		
28	Innovative	and	Personalised	Medicine,	European	Commission,	Belgium		
29	Office	of	Human	Research	Affairs,	Partners	HealthCare,	Boston	MA	
30	Department	of	Pharmacy,	School	of	Health	Sciences,	University	of	Patras,	Greece	
31	Laboratory	for	Molecular	Medicine,	Partners	Healthcare	Systems,	Boston	MA	
3 
 
32	Department	of	Pharmaceutical	Sciences,	St.	Jude	Children’s	Research	Hospital,	Memphis	TN	
33	Carmel	Medical	Center	Department	of	Community	Medicine	and	Epidemiology,	Clalit	
National	Personalized	Medicine	Program,	Israel	
34	Vanderbilt	University	School	of	Medicine,	Nashville,	TN		
35	Program	in	Personalized	and	Genomic	Medicine,	University	of	Maryland	School	of	Medicine,	
Baltimore,	MD	
36	Department	of	Biotechnology,	Ministry	of	Science	and	Technology,	Govt.,	India	
37	Duke-National	University	of	Singapore	Graduate	Medical	School,	Singapore.	
38	Swedish	Research	Council,	Sweden	
39	Prince	of	Wales	Clinical	School,	University	of	New	South	Wales,	Australia	
40	Genomic	Medicine	Institute,	Geisinger	Health	System,	Danville,	PA		
41	National	University	of	Singapore,	Singapore	
42	Center	for	Applied	Genomics	and	Precision	Medicine,	Duke	University,	Durham,	NC	
This	paper	summarizes	the	deliberations	of	a	symposium	convened	by	the	National	Human	
Genome	Research	Institute	on	January	8-9,	2014,	to	examine	global	models	for	genomic	
medicine	implementation	and	opportunities	for	collaboration.			The	views	expressed	in	this	
article	are	those	of	the	individual	authors	and	do	not	necessarily	represent	the	views	of	their	
affiliated	organizations,	institutions,	or	government	agencies.		
Correspondence:	
	
Teri	Manolio,	M.D.,	Ph.D.	
Director,	Division	of	Genomic	Medicine	
National	Human	Genome	Research	Institute	
5635	Fishers	Lane,	Room	4113,	MSC	9305	
Bethesda,	MD	20892-9305	
Phone:	301-402-2915	
E-mail:	manolio@nih.gov	
	
Word	count:		 Abstract:	243	
Text:	3,990	
Conflict	of	Interest	Notification:		 	
4 
 
ABSTRACT	
Advances	in	high-throughput	genomic	technologies	coupled	with	a	growing	number	of	
genomic	results	potentially	useful	in	clinical	care	have	led	to	ground-breaking	genomic	
medicine	implementation	programs	in	various	nations.		Many	of	these	innovative	programs	
capitalize	on	unique	local	capabilities	arising	from	the	structure	of	their	health	care	systems	or	
their	cultural	or	political	milieu,	as	well	as	from	unusual	burdens	of	disease	or	risk	alleles.		Many	
such	programs	are	being	conducted	in	relative	isolation	and	might	benefit	from	sharing	of	
approaches	and	lessons	learned	in	other	nations.		The	National	Human	Genome	Research	
Institute	recently	brought	together	25	of	these	groups	from	around	the	world	to	describe	and	
compare	projects,	examine	the	current	state	of	implementation	and	desired	near-term	
capabilities,	and	identify	opportunities	for	collaboration	to	promote	the	responsible	
implementation	of	genomic	medicine.			
	 The	wide	variety	of	nascent	programs	in	diverse	settings	demonstrates	that	implementation	
of	genomic	medicine	is	expanding	globally	in	varied	and	highly	innovative	ways.		Opportunities	
for	collaboration	abound	in	the	areas	of	evidence	generation,	health	information	technology,	
education,	workforce	development,	pharmacogenomics,	and	policy	and	regulatory	issues.			
Several	international	organizations	that	are	already	facilitating	effective	research	collaborations	
should	engage	to	ensure	implementation	proceeds	collaboratively	without	potentially	wasteful	
duplication.		Efforts	to	coalesce	these	groups	around	concrete	but	compelling	signature	
projects,	such	as	global	eradication	of	genetically-mediated	drug	reactions	or	developing	a	truly	
global	genomic	variant	data	resource	across	a	wide	number	of	ethnicities,	would	accelerate	
appropriate	implementation	of	genomics	to	improve	clinical	care	world-wide.			
	
Key	words:	medical	genomics,	implementation,	global	collaborations,	practice	standards,	
pharmacogenomics,	personalized	medicine,	precision	medicine	
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INTRODUCTION	
	 The	growing	number	of	genomic	advances	directly	relevant	to	disease	diagnosis,	treatment,	
and	prevention	[1]	coupled	with	the	declining	cost	of	detection	of	genomic	variation	[2]	has	
opened	the	door	to	using	genomic	technologies	in	routine	clinical	care.		Among	the	many	
challenges	to	widespread	implementation	of	genomic	medicine,	the	lack	of	evidence	of	impact	
on	clinical	outcomes	is	key	and	looms	large	in	terms	of	the	effort	needed	to	address	it	[3].		
Other	barriers	include	needs	for	standardization	and	quality	assurance	of	genomic	data	
produced	by	clinical	laboratories,	clinical	informatics	infrastructure	for	managing	genomic	
information,	education	for	health	professionals	and	patients	in	using	the	information,	and	
policies	for	data	sharing	that	permit	ongoing	capture	of	generalizable	clinical	experience	in	
what	has	been	termed	“evidence-generating	medicine”	[4].			
	 A	host	of	ongoing	efforts	worldwide	to	establish	national	implementation	strategies	for	
genomic	medicine	reflects	the	growing	level	of	discovery	and	understanding	in	this	area	[5-8],	
but	many	such	efforts	are	being	conducted	in	relative	isolation.		Sharing	strategies,	data,	and	
standards	could	minimize	wasteful	duplication	and	speed	progress	in	identifying	genomics-
based	interventions	most	likely	to	improve	patient	care	and	enhance	outcomes	for	patients	and	
populations.		Early	efforts	at	such	collaborations	include	the	European	Association	for	
Predictive,	Preventive,	and	Personalised	Medicine	(EPMA)	[9],	the	European	Commission’s	
EuroBioForum	and	Observatory	[10]	and	the	Genomic	Medicine	Alliance	[11,12],	which	have	
spearheaded	promising	projects	such	as	the	application	of	genome	sequencing	in	
pharmacogenomics	and	development	of	online	pharmacogenomic	resources.		Related	efforts	
include	the	International	Rare	Disease	Research	Consortium	(IRDiRC),	developing	new	
diagnostic	strategies	and	therapies	for	rare	diseases	[13];	the	Global	Alliance	for	Genomics	and	
Health	(GA4GH),	promoting	responsible	sharing	of	genomic	data	for	research	[14];	and	
EuroGentest,	drafting	professional	guidelines	for	diagnostic	DNA	sequencing	[15].				
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To	assess	the	current	global	state-of-the-art,	and	building	on	early	genomic	medicine	
implementation	efforts	in	the	U.S.	[3],	the	National	Human	Genome	Research	Institute	[16]	and	
the	Institute	of	Medicine	of	the	U.S.	National	Academy	of	Sciences	convened	90	leaders	in	
genomic	medicine	from	the	U.S.	and	25	other	countries	on	5	continents	for	a	“Global	Leaders	in	
Genomic	Medicine”	symposium	in	January	2014	[17].		While	the	organizers	attempted	to	
identify	and	invite	every	nation	working	in	genomic	medicine	implementation,	participation	
was	undoubtedly	limited	by	the	lack	of	systematic	information	on	such	efforts	and	limited	
funding	for	participation.			Despite	these	constraints,	several	countries	outside	of	Europe,	the	
U.K.	and	the	U.S.	were	able	to	take	part,	such	as	Australia,	Estonia,	India,	Israel,	Japan,	Korea,	
Kuwait,	New	Zealand,	Singapore,	Sri	Lanka,	and	Thailand	[see	full	list	of	participating	countries	
at	http://www.genome.gov/27555775].		This	paper	summarizes	the	efforts	described	by	these	
groups,	with	emphasis	on	regions	with	unique	capabilities	due	to	the	structure	of	their	health	
care	systems,	cultural	or	political	readiness	for	implementation,	or	unusual	disease	burdens	or	
risk-allele	frequencies;	the	current	state	of	implementation	in	these	countries	and	desired	
capabilities	in	the	next	3-5	years;	and	opportunities	for	collaboration	to	promote	the	
responsible	implementation	of	genomic	medicine.			
	
BRIEF	LANDSCAPE	OF	INTERNATIONAL	GENOMIC	MEDICINE	PROJECTS	
	 In	an	informal	poll	of	participants	prior	to	the	symposium,	nearly	all	sites	reported	some	
genomic	medicine	capabilities	such	as	using	genotyping	and/or	genome	or	exome	sequencing	
for	disease	prediction,	diagnosis,	prevention,	and	treatment	as	well	as	family	counseling	(Table	
1).		Over	70%	of	respondents	reported	availability	of	clinical	sequencing	resources	for	cancer	
treatment,	rare	disease	diagnosis,	and	microbial	pathogen	identification	in	specialized	centers	
only,	while	another	~10%	reported	these	capabilities	to	be	widely	available.		Conversely,	more	
than	half	reported	lack	of	any	capabilities	for	newborn	sequencing,	RNA	profiling,	
metabolomics	or	proteomics.		Substantial	gains	in	availability	of	clinical	genomic	resources	
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were	desired	in	the	next	3-5	years,	particularly	for	pharmacogenomics,	pathogen	identification,	
genetic	counseling,	electronic	medical	records,	and	clinical	decision	support.		Several	other	
technologies,	such	as	newborn	sequencing,	rare	disease	diagnosis,	and	RNA	profiling,	were	
projected	to	become	available	in	specialized	centers	where	no	capability	currently	exists.		
Barriers	to	global	implementation	of	genomic	medicine	(Table	2)	were	similar	to	those	
identified	in	a	2012	survey	examining	U.S.	genomic	medicine	implementation	efforts	[3],	
reinforcing	the	notion	that	the	global	genomic	medicine	community	shares	important	
challenges	and	interests.			
	 The	most	common	implementation	efforts	involve	cancer	genomics,	large-scale	exome	or	
whole-genome	sequencing,	and	pharmacogenomics,	while	several	current	projects	focus	on	
particular	national	priorities	(Table	3).		National	efforts	to	build	infrastructure	for	genome	
sequencing	and	other	genomic	and	information	technologies	are	underway	in	nearly	all	
countries	represented.		Perhaps	the	largest	such	effort	is	the	UK	project	to	sequence	100,000	
whole	genomes	by	2017	through	the	creation	of	Genomics	England	[18].		This	project	builds	on	
a	national	strategy	to	link	National	Health	Service	(NHS)	electronic	medical	records	(EMRs)	to	
research	and	development	of	genomic	medicine	[5,19],	focusing	initially	on	NHS	patients	with	
cancer	and	rare	and	infectious	diseases.		The	sequenced	genomes	will	be	analyzed	to	enhance	
each	patient's	clinical	care	as	well	as	create	a	research	dataset	of	genomic	data	linked	to	EMRs.		
Genomics	England	also	aims	to	train	the	wider	health	care	community	in	using	the	technology	
and	will	build	secure	data	linkages	to	the	NHS	to	ensure	the	effort	leads	to	better	patient	care.		
Pilot	studies	of	2,000	patients	with	rare	inherited	diseases	will	be	completed	by	early	2015,	and	
pilot	studies	of	3,000	patients	with	lung,	breast,	and	colon	cancer	began	in	late	2014.		The	main	
study	will	involve	sequencing	of	30,000	whole	genomes	per	year	in	these	three	emphasis	areas	
through	2017	and	should	produce	a	rich	infrastructure	of	next-generation	genome	sequencing	
centers,	a	sample	pipeline	and	biorepository,	and	large-scale	data	resources	for	producing	new	
diagnostics	and	therapies.			
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	 Belgium	is	also	building	a	national	genome-sequencing	pipeline,	the	Belgian	Medical	
Genomics	Initiative	(BeMGI	[20])--	a	comprehensive	network	of	scientists	and	clinicians	
intended	to	boost	research,	translate	genomics	into	clinical	care,	and	prepare	the	next	
generation	of	researchers	and	clinicians	to	use	genomic	technologies.		Important	current	efforts	
are	devoted	to	collecting	and	sharing	variant	frequency	data	and	translating	next	generation	
genome	sequencing	into	clinical	practice.		Similarly,	the	Estonian	government	recently	
approved	the	Pilot	Program	for	Personal	Medicine,	involving	the	sequencing	of	5,000	Estonians	
and	development	of	an	Estonian-specific	genotyping	array,	coupled	with	automated	decision	
support	and	training	of	physicians	to	use	the	results	in	everyday	practice.		This	comprehensive	
approach	will	be	pilot	tested	in	50,000	individuals	within	the	Estonian	Biobank	[21]	and	linked	
with	Estonia’s	rich	national	EMR	system,	through	which	all	residents	of	Estonia	can	access	their	
personal	medical	information	via	a	smartcard-based	National	Identity	Card.		If	successful,	the	
resulting	array-based	test	will	then	be	offered	to	all	Estonian	residents	ages	35-65	years,	
yielding	a	database	of	up	to	500,000	individuals	with	longitudinal	EMR,	genotype,	and	
prescription	data	for	use	in	clinical	disease	risk	assessment	and	drug	response	prediction	as	well	
as	in	research.			
Israel’s	Clalit	health	system	has	established	a	national	laboratory	that	provides	all	medical	
institutes	in	Israel	with	sequencing-based	panels	assessing	tissue	and	germline	genomic	
changes	for	risk	and	treatment	response.		It	is	also	testing	extensively	for	founder	mutations	in	
different	disease	states	and	is	developing	models	of	primary	care	in	which	patients	will	be	
routinely	tested	with	broad	genomic	panels	and	by	staff	trained	to	interpret	genomic	results.		In	
Australia,	newly	developing	comprehensive	cancer	centers	are	integrating	genomics-based	
cancer	research,	patient	care,	and	education	while	giving	patients	access	to	the	latest	
experimental	protocols	and	drugs.		Several	other	countries	such	as	Korea	and	Kuwait	are	
pursuing	more	limited	genome	sequencing	programs,	some	in	close	collaboration	with	the	
private	sector,	to	build	capacity	and	expertise.		These	and	many	other	participating	nations	
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expressed	willingness	to	deposit	their	resulting	sequence	and	phenotype	data	in	widely	
accessible	databases	such	as	ClinVar	[22]	or	dbGaP	[23].		Such	sharing	will	not	only	facilitate	
interpretation	of	human	genomic	variation	globally	but	will	also	give	external	visibility	to	these	
nations’	emerging	programs	and	better	integrate	their	scientists	into	the	international	
genomics	research	community.			
	 Canada’s	Genomics	and	Personalized	Health	Competition	(GAPH)	is	a	somewhat	different	
approach	to	building	national	genomics	capacity	and	assessing	the	cost-effectiveness	and	
impact	of	genomic	technologies	on	patient	outcomes	[8].		Seventeen	projects	have	been	
funded	to	support	genomic	medicine	implementation	and	related	research	in	health	
administration,	health	technology,	and	comparative	effectiveness.		Close	involvement	of	the	
private	sector	is	an	important	and	innovative	component	and	is	reflected	in	the	participation	of	
19	biotechnology-oriented	companies	in	the	project	teams.		Private	sector	involvement	is	also	
critical	to	Kuwait’s	Genatak	sequencing	initiative	in	which	patients	pay	for	their	whole	genome	
sequencing	themselves	[24].		Japan	is	implementing	a	program	somewhat	similar	to	Canada’s	
GAPH	in	its	“Implementation	of	Genomic	Medicine	Project”	to	establish	a	network	of	genomics-
focused	biobanks,	build	a	comprehensive	genomic	variation	database,	and	perform	studies	to	
assess	clinical	efficacy	and	utility	of	genomic	information	in	clinical	practice.	
	 A	third	approach--	utilizing	highly	focused	pilot	programs	to	build	capacity	and	demonstrate	
effectiveness	before	full-scale	implementation--	capitalizes	on	disproportionate	disease	
burdens	or	unique	capabilities	within	a	given	country.		Luxembourg’s	Centre	for	Systems	
Biomedicine,	for	example,	is	leveraging	local	expertise	in	neurobiology,	pathway	analysis,	and	
community-driven	annotation	[25,26]	to	create	an	interactive	map	charting	genetic	and	
molecular	underpinnings	of	Parkinson	disease	[27].		This	will	be	integrated	with	genome	
sequence	data	to	facilitate	early	diagnosis	and	molecular	stratification	of	the	disease.		
Singapore‘s	Personalized	OMIC	Lattice	for	Advanced	Research	and	Improving	Stratification	
(POLARIS)	project	takes	advantage	of	local	expertise	and	interest	in	genomics	and	
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ophthalmology	in	launching	a	pilot	effort	of	TGFBI	sequencing	to	assess	genetic	risk	for	stromal	
corneal	dystrophies	[28].		This	will	be	followed	by	implementation	of	a	90-gene	panel	targeting	
gastrointestinal	cancers,	diseases	of	high	burden	in	Singapore,	in	a	systematic	effort	to	develop	
a	nationwide	framework	for	genetic	and	genomic	testing.			
	 Thailand’s	Ministry	of	Public	Health	and	Ramathibodi	Hospital	are	focusing	on	a	condition	
occurring	at	unusually	high	frequency	in	that	region	and	recently	shown	to	have	strong	genetic	
determinants.		Stevens-Johnson	Syndrome/Toxic	Epidermal	Necrolysis	(SJS/TEN)	is	a	
devastating	and	often	fatal	cutaneous	reaction	to	medications	that	is	largely	mediated	by	high-
risk	HLA	alleles.		Thailand	has	one	of	the	highest	rates	of	SJS/TEN	in	the	world,	mainly	
attributable	to	high	frequency	of	these	risk	alleles	and	use	of	causative	drugs	[28].		Ramathibodi	
Hospital	has	launched	a	“pharmacogenetics	card”	that	provides	patients’	HLA	variant	
information	predicting	risk	of	SJS/TEN	from	specific	drugs	on	a	patient-carried	wallet	card.		
Initial	cost-effectiveness	studies	have	been	sufficiently	convincing	that	the	Thai	government	has	
agreed	to	provide	the	testing	as	standard	of	care	[29-31].		Singapore	has	come	to	the	same	
conclusion	and	Asian	patients	being	considered	for	carbamazepine	are	offered	HLA-B*15:02	
screening	[32,33].							
	 These	three	briefly	described	approaches—population-wide	genomic	sequencing	and	EMR	
integration,	coordinated	nationwide	genomic	medicine	research	programs,	and	localized	efforts	
focusing	on	unique	capabilities	or	needs—demonstrate	that	no	country	has	a	monopoly	on	
implementation	of	genomic	medicine.		Quite	the	contrary,	implementation	is	expanding	
globally	in	diverse	and	highly	innovative	ways.		Yet	here	again,	as	noted	in	early	U.S.	genomic	
medicine	implementation	programs	[3],	many	of	these	efforts	are	being	conducted	in	relative	
isolation	with	little	interaction	or	collaboration.		Given	the	rapid	growth	of	the	genomics-based	
biotechnology	sector	[34]	and	the	pressure	on	university-based	researchers	to	commercialize	
their	work	[35],	some	degree	of	competition	is	to	be	expected.		Still,	willingness	to	share	
effective	tools	and	strategies	through	consortia	such	as	the	Electronic	Medical	Records	and	
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Genomics	(eMERGE)	Network	[36],	the	Pharmacogenomics	KnowledgeBase	(PharmGKB	[37]),	
the	Implementing	Genomics	in	Practice	(IGNITE)	Network	[38],	and	the	GAPH,	IRDiRC,	and	
GA4GH	efforts	described	above	demonstrate	the	possibilities	for	synergistic	global	interactions.		
Indeed,	the	international	collaborations	identified	above	[11-14]	predominantly	focusing	on	
research	illustrate	the	potential	power	of	such	alliances	and	the	readiness	of	the	genomics	
community	to	form	them.		Given	the	critical	need	for	clinical	evidence	generation	and	
evaluation	of	genomic	medicine	interventions,	and	the	value	of	harnessing	information	from	
diverse	populations	to	capture	the	immensity	of	human	genomic	variation,	international	
collaborative	projects	in	clinical	implementation	are	an	obvious	solution.			
	
OPPORTUNITIES	FOR	INTERNATIONAL	COLLABORATION		
Areas	that	could	benefit	from	multinational	collaborations	in	genomic	medicine	
implementation	include	evidence	generation,	health	information	technology,	education,	
workforce	development,	pharmacogenomics,	and	policy	and	regulatory	issues	including	
economic	evaluation	(Table	4).		Recognizing	the	important	differences	among	countries	in	
culture,	public	perceptions,	governance	structures,	health	care	systems,	resources,	and	
infrastructure--	and	notwithstanding	some	clear	biologic	differences	in	allele	frequencies	and	
prevalent	diseases--	there	is	so	much	to	be	learned	and	the	potential	for	unnecessary	
duplication	is	so	great	that	some	degree	of	coordination	and	sharing	of	results	is	critical.			
	
Evidence	Generation	
Generating	evidence	of	the	value	of	genomics	for	patients,	clinicians,	and	health	care	
systems	is	among	the	most	expensive	of	potential	international	collaborations	and	already	has	
considerable	work	ongoing,	as	detailed	above.		Despite	differences	in	health	care	delivery	
systems,	much	can	be	learned	from	clinical	trials	and	demonstration	projects	in	other	settings,	
as	is	clear	from	other	disciplines	[39-41].		International	collaborations	have	amply	shown	the	
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speed	with	which	multi-national	consortia	can	answer	questions	that	few	countries	can	tackle	
on	their	own,	as	demonstrated	for	survival	after	myocardial	infarction	[42],	global	burden	of	
disease	[43],	and	HIV/AIDS	[44].		Given	the	many	genomic	medicine	implementation	projects	
already	in	progress,	a	critical	first	step	is	to	catalog	ongoing	evidence-generating	projects	and	
the	genomics-based	interventions	they	can	be	used	to	evaluate.		Such	a	catalog	should	include	
the	availability	of	these	projects’	specimens	and	data,	including	patient	data,	for	additional	
research.		Registries	such	as	the	Australian	New	Zealand	Clinical	Trials	Registry	[45],	the	
European	Union	Clinical	Trials	Register	[46],	and	ClinicalTrials.gov	[47,48],	could	conceivably	be	
adapted	to	receive	and	provide	information	about	genomic	medicine	evidence	generation	
projects.			
To	fill	gaps	in	evidence	identified	by	surveying	the	catalogued	projects,	a	key	next	step	is	to	
identify	countries	and	health	care	systems	willing	to	enable	access	to	patient	data,	within	
appropriate	constraints	of	policy,	privacy,	and	consent.		Differences	across	systems,	including	
but	not	limited	to	language,	will	also	need	to	be	evaluated	to	find	those	most	scientifically	
advantageous	for	combined	analysis.		Systems	will	then	be	needed	to	capture	relevant	
outcomes	from	EMRs	and	other	clinical	systems	and	settings,	and	to	analyze	and	interpret	the	
findings.		Funding	for	these	efforts	will	of	course	be	needed,	but	to	the	degree	that	studies	can	
be	embedded	in	ongoing	clinical	care,	costs	of	evidence	generation	may	be	significantly	
reduced	[49-51].								
Another	important	step	is	to	define	standards	for	what	constitutes	sufficient	evidence	to	
implement	a	genomic	medicine	intervention,	which	will	likely	vary	depending	on	whether	a	
gene,	genetic	variant,	or	genetic	test	is	under	consideration	and	whether	it	would	be	used	for	
risk	prediction,	diagnosis,	treatment,	or	understanding	of	pathogenesis.		Additional	standards	
for	performance	of	genetic	tests,	with	more	emphasis	on	interpretation	and	clinical	decision	
support,	will	also	be	needed,	as	will	standards	for	incorporating	genomic	information	into	the	
EMR.		Once	a	sufficient	body	of	evidence	is	available,	professional	practice	guidelines	suitable	
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to	a	specific	setting	or	country	will	need	to	be	developed.		Along	these	lines,	Australia	and	New	
Zealand’s	National	Health	and	Medical	Research	Councils	are	developing	a	framework	and	
principles	to	facilitate	the	translation	of	genomic-based	tests	from	discovery	to	health	care	[52].	
	
Health	Information	Technology		
	 Few	areas	of	medicine,	with	the	possible	exception	of	imaging,	are	as	dependent	on	
information	technology	(IT)	as	genomics,	given	the	vastness	of	genome	sequence	data.		
Although	sequence	data	can	and	likely	should	be	stored	and	manipulated	outside	the	EMR	[53],	
extracting	even	the	clinically	relevant	genomic	variants	found	in	a	single	patient	is	a	challenging	
task.		Due	to	the	rapid	evolution	of	knowledge	about	clinically	relevant	variants	and	the	
changing	clinical	situation	of	an	individual	patient,	a	dynamic	approach	is	needed	for	presenting	
variant	information	only	when	it	can	potentially	make	a	difference	in	that	individual’s	care	[54].		
In	addition,	genome	sequence	data	should	ideally	be	retrievable	for	use	later	in	a	patient’s	
clinical	course,	and	throughout	their	lifetime,	and	should	be	accessible	to	other	specialists	and	
care	systems	as	needed.	
	 A	critical	first	step	is	to	define	the	key	data	elements	that	should	be	stored	in	the	EMR,	so	
that	construction	of	IT	systems	can	accommodate	them.		Truly	global	resources	for	actionable	
clinical	genomic	variants	are	urgently	needed	and	could	build	on	current	efforts	such	as	the	
Clinical	Genome	Resource	(ClinGen)	[55,56]	that	includes	the	ClinVar	database	of	the	National	
Center	for	Biotechnology	Information	[22].		Other	federated	databases	necessary	to	interpret	
variants	and	implement	genomic	medicine,	such	as	the	international	Exome	Aggregation	
Consortium	(ExAC)	Data	Set	[57]	and	the	Sanger	Institute’s	Database	of	Chromosomal	
Imbalance	and	Phenotype	in	Humans	Using	Ensembl	Resources	(DECIPHER)	[58]	will	also	be	
needed,	as	will	collection	and	aggregation	of	worldwide	genomic	variant	data	and	agreed-upon	
strategies	to	create	relevant	reference	genome	sequences	where	needed	to	underpin	these	
resources.		Use	of	available	and	widely	accepted	controlled	vocabularies	(ontologies)	for	
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phenotypes	and	avoidance	of	proliferation	of	local	or	regional	ontologies	will	be	essential	to	
interpretation	of	variants	and	sharing	of	information.		The	Innovative	Medicine	Initiative	(IMI)	
project	"ETRIKS,"	funded	jointly	be	the	European	Union	and	industry,	aims	to	create	and	run	an	
open,	sustainable	research	informatics	and	analytics	platform	for	sharing	data	and	supporting	
translational	research	in	personalized	medicine	[59].			
	
Education	and	Workforce	Development	
	 Educational	needs	will	vary	by	the	group	to	be	targeted,	be	they	health	practitioners	or	the	
lay	public	(Table	4).		Assessments	of	the	currently	available	genomic	professional	workforce	and	
estimates	of	workforce	needs,	while	likely	to	show	shortages	at	almost	every	level	in	almost	
every	country,	will	help	to	prioritize	educational	programs.		Programs	should	also	be	tailored	to	
the	settings	in	which	genomics-based	care	is	expected	to	be	delivered,	such	as	through	routine	
primary	care,	specialized	genetic	clinics,	or	pharmacists	or	other	allied	health	personnel.		
Competencies	for	health	care	professionals	at	multiple	levels	within	a	given	system	will	need	to	
be	defined	and	appropriate	educational	programs	developed	[60,61].		Integration	of	genomics	
into	health	professional	curricula	will	become	increasingly	necessary	[62].		As	materials	
developed	in	one	part	of	the	world	are	shared	globally,	translation	for	language	and	cultural	
appropriateness	will	be	needed,	but	will	be	worthwhile	if	effective	training	paradigms	and	best	
practices	can	be	identified	and	shared	rather	than	invented	(or	re-invented)	de	novo.		Relying	
increasingly	on	distance	learning	and	other	online	tools	[63,64]	will	facilitate	rapid	
implementation	and	global	spread.			
	 Education	and	engagement	of	the	public,	including	policy-makers	and	regulators,	should	
also	build	on	available	resources	that	can	be	translated	and	adapted	to	specific	cultures	[65,66].		
A	“clearinghouse”	for	accumulated	information	and	introduction	of	novel	educational	materials	
would	be	useful.		As	elsewhere,	customizing	materials	to	the	culture	of	the	target	audience	will	
be	critical	for	facilitating	understanding	and	acceptance.	
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Pharmacogenomics	
Several	pharmacogenomic	applications	have	already	been	widely	implemented	in	the	U.S.	
and	elsewhere	[1,67,68]	and	could	represent	an	“early	win”	ripe	for	trans-national	sharing	of	
best	practices	and	lessons	learned.		Effective	international	collaborations	have	been	formed	to	
study	the	genomics	of	adverse	drug	reactions	[69-71],	but	actual	implementation	efforts	have	
been	more	isolated.		The	Pharmacogenetics	for	Every	Nation	Initiative	(PGENI)	is	a	notable	
exception,	promoting	integration	of	pharmacogenomics	into	public	health	decision-making	by	
using	population-specific	risk	allele	frequency	data	for	nationally-tailored	drug	selection	in	
developing	nations	[72].		Guidelines	from	the	Pharmacogenomics	Research	Network’s	Clinical	
Pharmacogenetics	Implementation	Consortium	(CPIC	[73]),	which	provides	recommendations	
on	drug	selection	and	dosing	based	on	an	individual’s	genotypic	data,	are	also	increasingly	used	
clinically.	
Collaborative	implementation	efforts	in	pharmacogenomics	could	promote	generation	of	an	
improved	evidence	base,	focusing	particularly	on	inexpensive	drugs	characterized	by	treatment	
failure	such	as	clopidogrel	[74],	or	severe	adverse	reactions	such	as	abacavir	[75],	and	likely	to	
be	limited	to	a	genetically	defined	subset.		The	pharmacogenomics	card	for	avoidance	of	
SJS/TEN	being	implemented	in	Thailand,	as	described	above,	is	an	elegantly	simple	and	practical	
approach	for	reducing	the	incidence	of	one	of	the	most	feared	of	all	adverse	drug	reactions.		
Wider	implementation	of	this	approach	in	neighboring	countries	with	similar	health	systems	
and	ancestries,	with	an	ultimate	aim	of	global	eradication	of	genetically-related	SJS/TEN,	
appears	to	be	an	achievable	goal	around	which	an	international	genomic	medicine	collaborative	
could	coalesce.			
Application	of	whole-genome	sequencing	in	pharmacogenomics	could	eventually	define	
fully	an	individual’s	personalized	pharmacogenomics	profile	[76].		Customizing	such	an	
approach	as	a	targeted	sequencing	effort	of	the	several	hundred	pharmacogenes	involved	in	
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drug	metabolism	and	transport,	or	the	smaller	subset	of	clinically	actionable	pharmacogenes	
[37]	would	reduce	costs	and	make	this	application	more	affordable	than	more	comprehensive	
sequencing	efforts		[77].	
	
Policy	and	Regulatory	Issues	
Multiple	international	initiatives	are	addressing	policy	needs	to	facilitate	data	sharing	in	
genomic	research,	particularly	the	Canadian-led	Public	Population	Project	in	Genomics	(P3G)	
[78]	and	GA4GH	[14,79].		Such	efforts	are	quite	relevant	to	genomic	medicine	implementation	
and,	as	with	the	evidence	realm,	an	assessment	of	current	activities	along	with	a	gap	analysis	
would	be	important	initial	steps.		Harmonizing	national	ethical	guidelines	and	regulatory	
frameworks	as	feasible	will	be	essential	for	successful	international	collaborations,	as	will	a	
more	complete	understanding	of	regional	laws	relevant	to	genomics	governing	research,	
privacy,	and	confidentiality.		In	evaluating	costs,	risks,	and	benefits	of	genomic	interventions,	
identifying	conditions	for	which	genomic	tools	could	have	the	greatest	impact	on	patient	and	
population	outcomes--	such	as	cancer,	metabolic	disorders,	HIV	therapy,	or	cystic	fibrosis--	
would	be	a	useful	first	step.		By	integrating	economic	assessments	into	translational	research	
not	only	can	the	utility	of	genomic	interventions	be	determined,	but	the	relative	value	of	such	
interventions	can	be	assessed	and	inform	health	care	decision-makers.		Expanding	single-
country	studies	of	cost-effectiveness	to	multiple	health	care	systems	may	help	identify	key	
underpinning	structural	components	that	promote	favorable	cost-benefit	ratios	[80].		Multi-
national	collaborations	will	be	particularly	valuable	for	examining	different	systems	and	models,	
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such	as	those	with	one	or	a	few	centralized	payers	that	can	provide	a	more	unified	and	
systematic	examination	of	the	decision-making	process.					
Useful	next	steps	include	conducting	a	more	systematic	mapping	effort	of	ongoing	
implementation	projects	worldwide	and	an	inventory	of	available	evidence	and	evidence-
generation	projects.		These	will	help	to	define	gaps	that	a	group	devoted	primarily	to	
implementation	can	fill	and	how	best	that	group	can	interact	with	existing	efforts.	
	
CONCLUSION	
	 The	wealth	of	international	programs	actively	engaged	in	genomic	medicine	
implementation,	and	the	potential	for	synergy	and	collaboration	among	them,	present	exciting	
opportunities	for	speeding	progress	and	improving	care.		Especially	in	this	online	age,	none	of	
these	projects	should	have	to	labor	in	isolation.		Several	organizations	are	already	showing	the	
power	of	the	international	genomics	community	to	form	effective	collaborations	around	
research	[10-14],	though	most	are	closer	to	the	generation	of	new	knowledge	through	research	
than	to	implementation	of	that	knowledge	for	improving	patient	care.		Engaging	and	building	
upon	the	ongoing	work	of	these	groups	will	be	critical	in	furthering	the	effort	without	wasteful	
duplication.		Coalescing	these	groups	around	concrete	but	compelling	signature	projects	may	
have	a	galvanizing	effect	that	will	facilitate	similar	programs	in	the	future.			
To	explore	these	possibilities,	several	participating	investigators	and	countries	have	formed	
a	Global	Genomic	Medicine	Collaborative	(G2MC)	hosted	by	the	U.S.	Institute	of	Medicine	as	
part	of	its	Genomic	Medicine	Roundtable	[81].		Goals	of	the	G2MC	are	to	serve	as	a	nexus	for	
genomic	medicine	activities	globally,	develop	opportunities	for	global	genomic	medicine	
implementation	and	outcomes	research,	and	capture	and	disseminate	best	practices	for	
genomic	medicine	implementation	across	the	global	community.			
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Recognizing	that	this	initial	survey	has	likely	failed	to	capture	many	relevant	projects	and	
interested	countries,	the	authors	invite	others,	particularly	scientists	and	policy-makers	
representing	their	governments’	genomic	medicine	implementation	efforts,	to	join	this	effort	
and	make	their	interests	known	to	the	authors	(particularly	G.G.,	G.P.,	and	J.W.).		Relevant	
projects	are	characterized	mainly	by	an	individual’s	genomic	results	being	used	in	their	clinical	
care,	and	by	the	commitment	of	participating	organizations	to	serving	the	needs	of	a	global	
community	of	patients,	researchers,	and	clinicians.		Genomic	medicine	has	the	potential	to	
dramatically	change	the	way	we	train	medical	professionals	and	deliver	health	care.		As	we	
work	toward	realizing	our	common	interests	in	the	appropriate	implementation	of	genomic	
medicine,	it	is	indeed	encouraging	to	know	that	none	of	us	need	tackle	these	challenges	alone.			
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Table	1.		Selected	current	and	desired	genomic	medicine	capabilities	across	participating	
countries/regions	(number	surveyed	=25).	
	
	 Today	(%)	 Desired	in	3-5	Years	(%)	
	
Capability	
Not	
at	all	
Specialized	
Centers	
Widely	
Available	
Not	
at	all	
Specialized	
Centers	
Widely	
Available	
Pharmacogenomics	 23	 66	 11	 17	 29	 56	
Germline	Sequencing	 23	 66	 11	 11	 72	 17	
Tumor	Sequencing	 17	 72	 11	 11	 60	 29	
Newborn	Sequencing	 64	 36	 0	 11	 72	 17	
Maternal-Fetal		Sequencing	 29	 65	 6	 11	 66	 23	
Rare	Disease	Diagnosis	 23	 71	 6	 6	 77	 17	
Microbial	Pathogen	Identification	 17	 72	 11	 11	 36	 53	
RNA	Profiling	 50	 50	 0	 11	 66	 23	
Metabolomics	 53	 47	 0	 11	 78	 11	
Proteomics	 64	 36	 0	 29	 60	 11	
Systematic	Family	History	 17	 36	 46	 6	 23	 71	
Genetic	Counselors	 23	 47	 30	 6	 17	 77	
Electronic	Medical	Record	 23	 47	 30	 6	 0	 94	
Clinical	Decision	Support	 33	 33	 33	 6	 0	 94	
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Table	2.		Barriers	to	genomic	medicine	implementation.	
• Lack	of	evidence	of	efficacy	or	effectiveness	of	genomic	interventions	and	related	co-
dependent	technologies*	
• High	cost	and/or	lack	of	reimbursement	for	tests	and	co-dependent	technologies	
• Need	for	evidentiary	thresholds	for	genomic	testing	
• Lack	of	consensus	on	what	investments	are	needed	in	research	and	health	care	capacity	
for	effective,	sustainable	implementation	
• Limited	access	to	educational	information		
• Lack	of	bioinformatics/EMR	infrastructure	to	order,	receive,	act	upon,	and	follow	up	
results	and	assess	impact	of	clinical	interventions	
• Lack	of	expertise	and	training	programs	in	genetics,	genomics,	informatics,	and/or	
statistics	
• Need	for	quality	control	standards	for	genome	technologies	
• Need	for	databases	with	genomic	variants	linked	to	clinical	phenotypes	
• Limited	access	to	reliable	standardized	genotyping	or	sequencing	platforms	
• Concern	over	consent	and	privacy	needs	
• Need	to	align	genomic	research	with	the	future	burden	of	disease	and	health	needs	of	
patients	and	populations	
• Need	to	align	development	of	genomic	tests	with	development	of	effective	co-
dependent	technologies	
• Need	to	consider	ethical	and	legal	aspects	of	the	‘ownership’	of	genomic	information	
• Need	to	manage	competing	interests	in	a	fair	and	transparent	manner	
	
* Co-dependent	technologies:	Health	technologies	that	depend	on	another	technology	to	
achieve	or	enhance	their	intended	effect,	such	as	a	diagnostic	test	used	to	determine	the	
patient	subgroup	most	likely	to	respond	to	a	new	medication	[82].	
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Table	3.	Examples	of	specialized	genomic	medicine	implementation	projects	in	participating	
countries	and	regions.			
	
Country	(Name	of	Project)	 Goals	of	Specialized	Programs	
Single	Country	Efforts	 	
Australia	 Develop	national	framework	for	translating	–omics	
discoveries	into	clinical	research	and	practice,	including	
advice	on	return	of	results	from	genomics	research	and	
clinical	testing	
Belgium	(Belgian	Medical	
Genomics	Initiative,	BeMGI)		
Create	national	framework	for	clinical	exome	sequencing,	
share	variant	frequency	data,	incorporate	into	international	
initiatives,	train	the	next	generation	of	researchers	and	
clinicians	[http://www.bemgi.be/]	
Canada	(Genomics	and	
Personalized	Health	
Competition)	
Assess	benefits	(including	economic	benefits)	of	genomic	
technology	to	patients	and	expand	capacity	for	clinical	and	
translational	research	in	17	diverse	projects	
[http://www.genomecanada.ca/en/portfolio/research/2012-
competition.aspx]	
Estonia	(Estonian	Program	for	
Personal	Medicine)	
Sequence	5K	individuals,	develop	Estonian	genotyping	array,	
pilot	of	50K	Estonian	Biobank	members,	offer	to	all	35-65	yo	
(~500K)	and	link	to	EMR	
France	 Create	national	network	of	molecular	genetics	laboratories,	
clinical	cancer	genetics	centers,	and	inter-regional	
sequencing	platforms	
India	 Develop	infrastructure	for	genomic	medicine	implementation	
including	disease	susceptibility	assessment	across	ethnic	
groups,	fetal	risk	prediction	and	anomaly	diagnosis,	and	
cancer	genomics	
Israel	 Use	genomics	in	cancer	treatment,	push	de-identified	family	
history	data	into	EMR	of	relatives	
Japan	(Implementation	of	
Genomic	Medicine	Project,	
IGMP)	
Use	genomics	for	optimized	diagnosis,	treatment	and	
prevention	
Korea	(Genome	Technology	to	
Business	Translation	Program)	
Use	genomics	to	develop	early	diagnosis	and	treatment	
approaches	for	personalized	and	preventive	medicine	
30 
 
Luxembourg	(Centre	for	
Systems	Biomedicine)	
National	Centre	of	Excellence	in	Early	Diagnosis	and	
Stratification	of	Parkinson’s	Disease	
Singapore	(POLARIS)		 Pilot	TGFBI	testing	for	disease	diagnosis	and	family	risk	
assessment	in	stromal	corneal	dystrophies,	then	implement	
90-gene	panel	for	gastrointestinal	cancers	
Sri	Lanka	 Use	SNP	genotyping	to	identify	thalassemia	carriers	and	
genetic	modifiers	to	convert	thalassemia	to	manageable,	
chronic	illness	
Thailand	(Pharmacogenomics	
and	Personalized	Medicine)	
Implement	PGx	card	to	identify	risk	for	top	ten	drugs	with	
risk	for	Stevens	Johnson	Syndrome/Toxic	Epidermal	
Necrolysis	(SJS/TEN),	integrated	with	nationwide	
pharmacovigilance	program		
United	Kingdom	(Genomics	
England)	
Sequence	100K	whole	genomes	and	link	to	National	Health	
Service	records	to	treat	individual	patients	and	better	
understand	cancer,	rare	and	infectious	diseases	
[http://www.genomicsengland.co.uk/]	
Multi-National	Efforts	 	
Genomic	Medicine	Alliance	 Build	collaborative	efforts	between	developed	and	
developing/low-income	countries,	genotype	
pharmacogenomically	relevant	variants	in	developing	
nations,	develop	national/ethnic	genetic	databases	using	a	
data	warehouse	approach,	engage	in	public	health	genomics	
projects	
Gulf	States	(Genatak)	 Laboratory	network	for	pre-marital,	pre-natal	and	post-natal	
detection	of	recessive	diseases,	genetic	counseling,	
personalized	cancer	treatment,	chronic	disease	risk	
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Table	4.		Opportunities	for	international	collaborations.	
	
Evidence	generation	 	
• Catalog	ongoing	evidence-generating	projects		
• Assess	availability	of	data	and	specimens	
• Define	standards	for	evidence	
• Establish	standards	for	genetic	and	genomic	tests		
• Encourage	development	of	professional	practice	guidelines	
• Identify	countries/systems	willing	to	enable	access	to	patient	data	
• Develop	systems	to	capture	outcomes	from	EMRs	and	other	clinical	systems		
	
Health	information	technology	 	
• Define	key	elements	that	should	be	stored	in	EHR	
• Identify	and	share	existing	IT	solutions	that	are	more	robust	and	generalizable	(clinical	
decision	support,	variant	databases,	informatics	pipelines)	
• Develop	global	resource	for	actionable	clinical	variants	
• Define	and	link	necessary	federated	databases	needed	to	implement	genomic	medicine	
• Collect	and	aggregate	gene	and	variant	data	(e.g.	EVS,	ClinVar)	
• Develop	controlled	vocabulary	for	phenotypes	(ontology);	identify	available	ontologies	
• Establish	clearinghouse	of	genomic	medicine	implementation	guidelines	
	
Education/workforce	development	 	
• Genomics	professionals	
o Collect	data	on	genomic	professional	workforce	and	training	in	different	
countries	
o Summarize	existing	workforce	surveys	and	conduct	new	ones	as	needed		
o Share	competencies	and	training	paradigms	
o Compare	training	paradigms	for	geneticists	and	identify	best	practices		
o Examine	extending	current	capabilities	by	telemedicine	and	other	remote	
approaches	
• Other	health	professionals	
o Examine	curricula	and	determine	where	genetics	competency	training	can	be	
accommodated	
o Define	necessary	genomic	competencies	for	trainees	at	completion	of	training,	
which	may	differ	across	regions/countries	
o Deploy	new	educational	tools,	such	as	distance	learning		
o Develop	region/country-specific	teaching	materials,	perhaps	on	common	
templates	
• Public	
o Adapt	existing	products	and	activities	such	as	DNA	Day	to	specific	cultures		
o Extend	to	students	at	secondary	school	level	
o Engage	patient	support	groups	to	sponsor	programs,	develop	and	distribute	
educational	materials	
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o Provide	clearinghouse	for	accumulated	educational	resources		
o Consider	novel	educational	paradigms	
	
Pharmacogenomics	 	
• Promote	improved	quality	of	evidence	base	for	pharmacogenomics	implementation	
• Prioritize	for	study	and	implementation	inexpensive	drugs	with	risk	of	treatment	failure	
or	severe	adverse	drug	reactions	likely	to	be	limited	to	genetically	defined	subset	
• Develop	and	pilot	large-scale	implementation	project	around	successful	programs	such	
as	global	eradication	of	genetically-mediated	SJS/TEN		
	
Policy	
• Data	sharing	and	regulatory	issues	
o Map	current	activities	and	issues	being	addressed	
o Perform	gap	analysis	
o Establish	“network	of	networks”	in	policy	development	to	share	information	
• Costs	and	benefits	
o Identify	burdens	of	disease	and	points	in	care	pathway	where	genomic	tools	
would	integrate	and	have	the	greatest	impact	on	outcomes	
o Improve	capacity	for	conducting	convincing	economic,	feasibility,	and	
sustainability	analyses		
o Perform	economic,	feasibility,	and	sustainability	analyses	from	perspective	of	
different	stakeholders	such	as	payers,	delivery	systems,	national	health	services		
o Engage	payers	and	payment	decision	processes	
o Work	in	and	learn	from	systems	with	one	or	a	few	centralized	payers	
	
	 	
